Pfizer and BioNTech win UK COVID-19 dispute

Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

CureVac and Acuitas wind up COVID-19 vaccine dispute

30 April 2024 Settlement comes after Acuitas alleged CureVac deliberately omitted its scientists as inventors on four US patents related to COVID-19 vaccines, claiming co-inventorship | Patents in suit relate to ongoing litigation with Pfizer and BioNTech.

Big Pharma

Big pharma firm hits back in COVID-19 tech dispute

6 September 2022 CureVac accuses Pfizer and its German partner of infringing patented tech in landmark COVID-19 treatment | The pharma giant says that the patents are invalid

Big Pharma

Vaccine makers hit back against patent claims

28 July 2022 German biotech and its US big pharma partner file counter complaint | Under-fire pair say they didn’t infringe patents | Claims reject earlier suit as an attempt to profit through legal threats.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Pfizer and BioNTech win UK COVID-19 dispute

More on this story

Editor's picks

Editor's picks

More features